The abstract is read at the publisher; the summary is JClub's.
Ribociclib plus nonsteroidal aromatase inhibitor improved 6-year overall survival versus nonsteroidal aromatase inhibitor alone in HR+/HER2- early breast cancer, with a 2.1% OS difference (HR 0.809).
- Why it matters: Early-stage HR+/HER2- patients at high risk still face recurrence and death, and longer-term survival evidence is needed beyond the primary invasive disease-free survival endpoint.
- What they did: In the phase 3 NATALEE trial, adults with HR+/HER2- EBC (stage IIA high-risk, IIB, or III) were randomized 1:1 to ribociclib 400 mg/day plus NSAI or NSAI alone, with a prespecified 6-year OS analysis (median follow-up 66.5 months).
- The result: The OS benefit (6-year ΔOS 2.1%; nominal 1-sided P = .019) was generally consistent across key subgroups, with supportive reductions in iDFS (ΔiDFS 5.3%; HR 0.741) and no new safety signals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.